Biology of Reproduction, Vol 44, 701-706, Copyright © 1991 by Society for the Study of Reproduction

ARTICLES

Antide-induced suppression of pituitary gonadotropin and ovarian steroid secretion in cynomolgus monkeys: premature luteolysis and prolonged inhibition of folliculogenesis following single treatment

K Gordon, RF Williams, DR Danforth and GD Hodgen
Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk 23510.

Administration of high-dose Antide to ovariectomized monkeys results in rapid, prolonged, and reversible inhibition of gonadotropin secretion. The present study examined whether similar long-term control would be manifested in the menstrual cycle of intact primates. Antide administration at a dose of either 3.0 or 18.0 mg/kg induced rapid suppression of bioassayable LH concentrations, precipitating a concurrent fall in serum progesterone concentrations from 7.9 +/- 3.6 and 5.8 +/- 1.0 ng/ml (mean +/- SEM) on the day of injection to 0.6 +/- 0.2 and 0.5 +/- 0.1 ng/ml by 2 days post-treatment, respectively. This Antide-induced luteolysis was accompanied by the premature onset of menses within 3 days. The next menses following Antide administration was delayed. Ultimately, folliculogenesis culminating in normal follicular-phase estradiol production, ovulation, and subsequent normal luteal-phase progesterone production did occur in all treated monkeys. Menses resumed 54 +/- 9 and 75 +/- 13 days after treatment with 3.0 and 18.0 mg/kg Antide, respectively. No allergic cutaneous or peripheral reactions were seen, even at the highest dose of Antide. Thus, the long duration of action of high-dose Antide reported earlier in ovariectomized monkeys is also demonstrated in intact primates. These findings, along with the apparent absence of histamine-release effects even at high doses, suggest that Antide is a GnRH antagonist deserving clinical evaluation.

This article has been cited by other articles:

				T. Hara, H. Araki, M. Kusaka, M. Harada, N. Cho, N. Suzuki, S. Furuya, and M. Fujino Suppression of a Pituitary-Ovarian Axis by Chronic Oral Administration of a Novel Nonpeptide Gonadotropin-Releasing Hormone Antagonist, TAK-013, in Cynomolgus Monkeys J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1697 - 1704. [Abstract] [Full Text] [PDF]

				P. Morales, C. Pasten, and E. Pizarro Inhibition of In Vivo and In Vitro Fertilization in Rodents by Gonadotropin-Releasing Hormone Antagonists Biol Reprod, October 1, 2002; 67(4): 1360 - 1365. [Abstract] [Full Text] [PDF]

				J. Schnorr, S. Oehninger, J. Toner, J. Hsiu, S. Lanzendorf, R. Williams, and G. Hodgen Functional studies of subcutaneous ovarian transplants in non-human primates: steroidogenesis, endometrial development, ovulation, menstrual patterns and gamete morphology Hum. Reprod., March 1, 2002; 17(3): 612 - 619. [Abstract] [Full Text] [PDF]

				P. Morales, B. Kerr, C. Oliva, E. Pizarro, and M. Kong Gonadotrophin-releasing hormone antagonists inhibit sperm binding to the human zona pellucida Hum. Reprod., August 1, 1999; 14(8): 2069 - 2074. [Abstract] [Full Text] [PDF]

				D. M. Duffy, D. R. Stewart, and R. L. Stouffer Titrating Luteinizing Hormone Replacement to Sustain the Structure and Function of the Corpus Luteum after Gonadotropin-Releasing Hormone Antagonist Treatment in Rhesus Monkeys J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 342 - 349. [Abstract] [Full Text]